{"title":"Enhancing the production of xylitol in recombinant Escherichia coli BL21 by metabolic engineering","authors":"Peize Wang, Fuyao Guan, Min Wu, Chuyang Yan, Xin Xu, Haoju Wang, Qihang Chen, Wei Sun, Jianying Huang, Ping Yu","doi":"10.1016/j.bej.2025.109876","DOIUrl":null,"url":null,"abstract":"<div><div>Xylitol, a pentose sugar alcohol with sweetness comparable to sucrose, has advantageous properties such as low caloric value and anti-cariogenic characteristics, leading to its extensive applications in food, chemical, and pharmaceutical industries. Current industrial production predominantly employs chemical catalytic methods, which suffer from high cost and environmental concerns. In contrast, microbial fermentation through metabolic engineering enables direct conversion of xylose to xylitol via microbial metabolism, demonstrating superior advantages of cost-effectiveness, environmental friendliness, and mild reaction conditions. This study developed an engineered <em>Escherichia coli</em> strain for high-efficiency xylitol production by implementing three key strategies: 1) introducing the heterologous xylose reductase gene <em>xyrB</em>, 2) optimizing NADPH cofactor supply, and 3) CRISPR/Cas9-mediated knockout of the competing pathway gene <em>xylA</em>. Subsequent fermentation condition optimization achieved remarkable production performance. Under optimized conditions with 15 g/L xylose and 10 g/L glucose in a 1-L shake flask system, the engineered strain <em>E. coli</em> BL21(DE3)/<em>ΔptsGΔxylA</em>-pETDuet-1 -<em>xyrB</em>-<em>zwf</em> demonstrated maximum xylitol production of 13.8 g/L (0.92 g/g xylose), representing significant improvement in bioconversion efficiency. This study contributes to the industrial production of xylitol by engineered strain <em>E. coli</em> BL21(DE3) via metabolic engineering.</div></div>","PeriodicalId":8766,"journal":{"name":"Biochemical Engineering Journal","volume":"223 ","pages":"Article 109876"},"PeriodicalIF":3.7000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical Engineering Journal","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1369703X25002505","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Xylitol, a pentose sugar alcohol with sweetness comparable to sucrose, has advantageous properties such as low caloric value and anti-cariogenic characteristics, leading to its extensive applications in food, chemical, and pharmaceutical industries. Current industrial production predominantly employs chemical catalytic methods, which suffer from high cost and environmental concerns. In contrast, microbial fermentation through metabolic engineering enables direct conversion of xylose to xylitol via microbial metabolism, demonstrating superior advantages of cost-effectiveness, environmental friendliness, and mild reaction conditions. This study developed an engineered Escherichia coli strain for high-efficiency xylitol production by implementing three key strategies: 1) introducing the heterologous xylose reductase gene xyrB, 2) optimizing NADPH cofactor supply, and 3) CRISPR/Cas9-mediated knockout of the competing pathway gene xylA. Subsequent fermentation condition optimization achieved remarkable production performance. Under optimized conditions with 15 g/L xylose and 10 g/L glucose in a 1-L shake flask system, the engineered strain E. coli BL21(DE3)/ΔptsGΔxylA-pETDuet-1 -xyrB-zwf demonstrated maximum xylitol production of 13.8 g/L (0.92 g/g xylose), representing significant improvement in bioconversion efficiency. This study contributes to the industrial production of xylitol by engineered strain E. coli BL21(DE3) via metabolic engineering.
期刊介绍:
The Biochemical Engineering Journal aims to promote progress in the crucial chemical engineering aspects of the development of biological processes associated with everything from raw materials preparation to product recovery relevant to industries as diverse as medical/healthcare, industrial biotechnology, and environmental biotechnology.
The Journal welcomes full length original research papers, short communications, and review papers* in the following research fields:
Biocatalysis (enzyme or microbial) and biotransformations, including immobilized biocatalyst preparation and kinetics
Biosensors and Biodevices including biofabrication and novel fuel cell development
Bioseparations including scale-up and protein refolding/renaturation
Environmental Bioengineering including bioconversion, bioremediation, and microbial fuel cells
Bioreactor Systems including characterization, optimization and scale-up
Bioresources and Biorefinery Engineering including biomass conversion, biofuels, bioenergy, and optimization
Industrial Biotechnology including specialty chemicals, platform chemicals and neutraceuticals
Biomaterials and Tissue Engineering including bioartificial organs, cell encapsulation, and controlled release
Cell Culture Engineering (plant, animal or insect cells) including viral vectors, monoclonal antibodies, recombinant proteins, vaccines, and secondary metabolites
Cell Therapies and Stem Cells including pluripotent, mesenchymal and hematopoietic stem cells; immunotherapies; tissue-specific differentiation; and cryopreservation
Metabolic Engineering, Systems and Synthetic Biology including OMICS, bioinformatics, in silico biology, and metabolic flux analysis
Protein Engineering including enzyme engineering and directed evolution.